GSK plc 6-K, filed Jul 31, 2023
GSK plc (GSK)
6-K
2023-07-31
For: 2023-07-31
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on July 31, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 31 July 2023, London UK
Jemperli (dostarlimab)
plus chemotherapy approved in the US as the first new frontline
treatment option in decades for dMMR/MSI-H primary advanced or
recurrent endometrial cancer
●
Jemperli is
the only immuno-oncology treatment approved in the frontline
setting for this patient population in combination with
chemotherapy
●
Patients with this type of
endometrial cancer face significant unmet need and typically
experience poor long-term outcomes with the current standard of
care
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug
Administration (FDA) has approved Jemperli (dostarlimab) in combination with
carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult
patients with primary advanced or recurrent endometrial cancer that
is mismatch repair deficient (dMMR), as determined by an
FDA-approved test, or microsatellite instability-high (MSI-H). The
supplemental Biologics License Application (sBLA) supporting this
new indication received Priority Review and was approved ahead of
the Prescription Drug User Fee Act action date.
Hesham Abdullah, Senior Vice President, Global Head of Oncology
Development, GSK, said: "Today's
expanded approval of Jemperli redefines
the treatment landscape for patients with dMMR/MSI-H primary
advanced or recurrent endometrial cancer. Until now, chemotherapy
alone has been the standard of care with many patients experiencing
disease progression. In the RUBY trial, Jemperli plus
chemotherapy demonstrated a 71% reduction in the risk of disease
progression or death versus chemotherapy in this patient
population, providing a statistically significant and clinically
meaningful benefit. These results and today's approval underscore
our belief in the potential for Jemperli to
transform cancer treatment as a backbone immuno-oncology
therapy."
With this approval, Jemperli is now indicated earlier in treatment in
combination with chemotherapy for patients with dMMR/MSI-H primary
advanced or recurrent endometrial cancer. Jemperli is already approved in the US as monotherapy
in adult patients with dMMR recurrent or advanced endometrial
cancer that has progressed on or following a prior
platinum-containing regimen in any setting and are not candidates
for curative surgery or radiation.
Matthew Powell, MD, Chief, Division of Gynecologic Oncology,
Washington University School of Medicine, and US principal
investigator of the RUBY trial said: "As
a clinician, I celebrate the practice-changing potential of
adding Jemperli to
chemotherapy for patients with dMMR/MSI-H primary advanced or
recurrent endometrial cancer who have had limited treatment
options. Based on the results from the RUBY clinical trial, I look
forward to the addition of Jemperli to
chemotherapy becoming a new standard of care for
patients."
Wenora Johnson, President, Board of Directors, Facing Our Risk of
Cancer Empowered (FORCE) said: "The
endometrial cancer community is thrilled by today's news, which
changes the treatment paradigm for a population with long-term
unmet needs. FORCE is grateful for the many participants and
researchers who contributed to this important study. As an
endometrial cancer survivor, I know how much this approval offers
hope for patients with primary advanced or recurrent dMMR/MSI-H
endometrial cancer."
The FDA approval is supported by interim analysis results from Part
1 of the RUBY/ENGOT-EN6/GOG3031/NSGO
phase III trial, which
reflect a robust median duration of follow-up of ≥ 25
months. The
trial met the primary endpoint of investigator-assessed
progression-free survival (PFS), demonstrating a statistically
significant and clinically meaningful benefit in patients treated
with Jemperli plus
carboplatin and paclitaxel in the dMMR/MSI-H population. In the
dMMR/MSI-H population, a 71% reduction in the risk of disease
progression or death was observed. Part 1 of the RUBY trial
continues to assess overall survival (OS) in the intent-to-treat
(ITT) population, a dual-primary endpoint alongside
investigator-assessed PFS.
The safety and tolerability profile for Jemperli plus carboplatin and paclitaxel was
generally consistent with the known safety profiles of the
individual agents. The most common treatment-emergent adverse
events (≥ 20%) in patients receiving Jemperli plus chemotherapy were rash, diarrhoea,
hypothyroidism and hypertension.
The RUBY trial data
(https://www.gsk.com/en-gb/media/press-releases/phase-iii-ruby-clinical-trial-demonstrates-potential-of-jemperli-plus-chemotherapy-to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial-cancer/)
were presented at the European Society for Medical Oncology (ESMO)
Virtual Plenary and Society of Gynecologic Oncology (SGO) Annual
Meeting on 27 March 2023, and were simultaneously published
in The
New England Journal of Medicine.
The sBLA supporting this new indication was reviewed under the FDA
Oncology Center of Excellence Project Orbis Framework, which
allowed for concurrent submission to and review by US and other
international regulatory authorities. As part of Project Orbis, the
application remains under review in Australia, Canada, Switzerland,
Singapore and the United Kingdom. A marketing authorisation
application is also under review by the European Medicines Agency.
About endometrial cancer
Endometrial cancer is one of the most common gynaecologic cancers
in developed countries,[[1]] and
there are about 60,000 new cases of endometrial cancer diagnosed
every year in the US. [[2]] Approximately
15-20% of patients with endometrial cancer will be diagnosed with
advanced disease at the time of diagnosis. [[3]]
[[4]] An
estimated 20-29% of all endometrial cancers are
dMMR/MSI-H.[[5]] Chemotherapy
used alone has been the current standard of care for primary
advanced or recurrent endometrial cancer, and many patients
eventually experience disease progression.[[6]]
About RUBY
RUBY is a two-part global, randomised, double-blind, multicentre
phase III trial of patients with primary advanced or recurrent
endometrial cancer. Part 1 is evaluating dostarlimab plus
carboplatin-paclitaxel followed by dostarlimab versus
carboplatin-paclitaxel plus placebo followed by placebo. Part 2 is
evaluating dostarlimab plus carboplatin-paclitaxel followed by
dostarlimab plus niraparib versus placebo plus
carboplatin-paclitaxel followed by placebo.
The dual-primary endpoints in Part 1 are investigator-assessed PFS
based on the Response Evaluation Criteria in Solid Tumours v1.1 and
OS. The statistical analysis plan included pre-specified analyses
of PFS in the dMMR/MSI-H and ITT populations and OS in the overall
population. Pre-specified exploratory analyses of PFS in the
mismatch repair proficient (MMRp)/microsatellite stable (MSS)
population and OS in the dMMR/MSI-H populations were also
performed. RUBY Part 1 included a broad population, including
histologies often excluded from clinical trials and had
approximately 10% of patients with carcinosarcoma and 20% with
serous carcinoma. In Part 2, the primary endpoint is
investigator-assessed PFS. Secondary endpoints in Part 1 and Part 2
include PFS per blinded independent central review, overall
response rate, duration of response, disease control rate,
patient-reported outcomes, and safety and
tolerability.
About Jemperli (dostarlimab)
Jemperli is a programmed
death receptor-1 (PD-1)-blocking antibody that binds to the PD-1
receptor and blocks its interaction with the PD-1 ligands PD-L1 and
PD-L2. [[7]]
In the US, Jemperli is
indicated in
combination with carboplatin and paclitaxel, followed
by Jemperli as
a single agent for the treatment of adult patients with primary
advanced or recurrent endometrial cancer that is mismatch repair
deficient (dMMR), as determined by an FDA-approved test, or
microsatellite instability-high (MSI-H), and as a single
agent for
adult patients with
mismatch repair-deficient (dMMR) recurrent or advanced endometrial
cancer, as determined by a US FDA-approved test, that has
progressed on or following a prior platinum-containing regimen in
any setting and are not candidates for curative surgery or
radiation. The
sBLA supporting the new indication in combination with carboplatin
and paclitaxel received Breakthrough Therapy designation from the
FDA. Jemperli is
also indicated in the US for patients with dMMR recurrent or
advanced solid tumours, as determined by a US FDA-approved test,
that have progressed on or following prior treatment and who have
no satisfactory alternative treatment options. The latter
indication is approved in the US under accelerated approval based
on tumour response rate and durability of response. Continued
approval for this indication in solid tumours may be contingent
upon verification and description of clinical benefit in a
confirmatory trial(s).
Jemperli was discovered by
AnaptysBio, Inc. and licensed to TESARO, Inc., under a
collaboration and exclusive license agreement signed in March 2014.
The collaboration has resulted in three monospecific antibody
therapies that have progressed into the clinic. These
are: Jemperli (GSK4057190), a PD-1 antagonist; cobolimab,
(GSK4069889), a TIM-3 antagonist; and GSK4074386, a LAG-3
antagonist. GSK is responsible for the ongoing research,
development, commercialisation, and manufacturing of each of these
medicines under the agreement.
Please see accompanying US Prescribing Information:
https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Jemperli/pdf/JEMPERLI-PI-MG.PDF.
GSK in oncology
GSK is committed to maximising patient survival through
transformational medicines, with a current focus on breakthroughs
in immuno-oncology and tumor-cell targeting therapies, and
development in haematologic malignancies, gynaecologic cancers and
other solid tumours.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Madison
Goring
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Camilla
Campbell
|
+44 (0)
7803 050238
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2022, and Q2 Results for 2023 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
References
[1] Faizan
U, Muppidi V. Uterine Cancer. [Updated
2022 Sep 5]. In: StatPearls [Internet]. Treasure Island (FL):
StatPearls Publishing; 2022 Jan-. Available at:
https://www.ncbi.nlm.nih.gov/books/NBK562313/.
[2] American
Cancer Society. Key Statistics For Endometrial Cancer.
https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html.
Updated February 14, 2022. Accessed March 29,
2023.
[3] Cerner
Enviza CancerMPact® Patient Metrics 2022.
CMP:CancerMPact® [Patient Metrics], Cerner Enviza. Available
from www.cancermpact.com. Accessed 11 May 2023.
[4] CancerMPact®
[Treatment Architecture], Cerner Enviza. Available from
www.cancermpact.com. Accessed 11 May 2023.
[5] Cerner
Enviza CancerMPact® [Treatment Architecture]. Available from
www.cancermpact.com. Accessed 14 Apr 2023.
[6] Halla
K. Emerging Treatment Options for Advanced or Recurrent Endometrial
Cancer. J Adv Pract Oncol. 2022 Jan;13(1):45-59. doi:
10.6004/jadpro.2022.13.1.4. Epub 2022 Feb 1. PMID: 35173988; PMCID:
PMC8805805.
[7] Laken
H, Kehry M, Mcneeley P, et al. Identification and characterization
of TSR-042, a novel anti-human PD-1 therapeutic antibody. European
Journal of Cancer. 2016;69,S102.
doi:10.1016/s0959-8049(16)32902-1.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
31, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|